L-citrulline Supplementation & Cold Exposure
Primary Purpose
Hypertension
Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
L-citrulline
Sponsored by

About this trial
This is an interventional prevention trial for Hypertension focused on measuring wave reflection, augmentation Index, heart rate variability, wasted left ventricular energy
Eligibility Criteria
Inclusion Criteria:
- Men
- Blood pressure lower than 140/90mmHg
- Age 18 to 35 years
- BMI 20-39 kg/m2
Exclusion Criteria:
- Blood Pressure >160/100 mmHg
- Asthma
- Glaucoma
- Herpes simplex
- Uncontrolled diabetes
- Neurological disease
- Cardiovascular disease
- Inflammatory disease
- Kidney disease
- Hormone replacement therapy (HRT)
- Amino acid/vitamin supplementation\
- Corticosteroids or non-steroidal anti-inflammatory drugs
- Any drug known to affect BP or heart rate
- Glycemic control drugs
- Lipids reducing drugs
- Participants should not consume > 12 alcoholic drink/week
- Smokers
- Regular Exercisers (>1.5 hour/week).
Sites / Locations
- FSU College of Human Sciences
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
L-citrulline
Maltodextrin
Arm Description
L-citrulline (100mg/kg of body weight per day for 2 weeks)
6g/day of placebo (maltodextrin)
Outcomes
Primary Outcome Measures
Blood Pressure
By measuring brachial and central (aortic and carotid) BP at rest and during physiological stress (cold exposure and handgrip test)
Secondary Outcome Measures
Autonomic control of heart rate
By measuring heart rate variability at rest and during physiological stress.
Full Information
NCT ID
NCT01462591
First Posted
October 27, 2011
Last Updated
August 4, 2014
Sponsor
Florida State University
1. Study Identification
Unique Protocol Identification Number
NCT01462591
Brief Title
L-citrulline Supplementation & Cold Exposure
Official Title
The Effects L-citrulline Supplementation on Arterial Stiffness, Wave Reflection, and Cardiac Autonomic Responses to Cold Exposure With Isometric Exercise
Study Type
Interventional
2. Study Status
Record Verification Date
August 2014
Overall Recruitment Status
Completed
Study Start Date
May 2011 (undefined)
Primary Completion Date
December 2011 (Actual)
Study Completion Date
May 2012 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Florida State University
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Cardiovascular disease (CVD) is considered the primary cause of death in the developed world. Large scale epidemiological studies indicate that prevalence of hypertension along with adverse cardiovascular events peak during the winter months. Moreover, during the winter months outdoor activities and physical stressors such as exercise have been associated with higher cardiovascular mortality when compared to other periods of the year. Although low environmental temperatures have been implicated as the triggering factor for cardiovascular complications, the mechanisms on how cold exposure increase cardiovascular morbidity and mortality remain to be elucidated. However, new research suggests that cold exposure may induce increases in cardiac sympathetic activity, endothelial damage and increased arterial stiffness of central arteries. Cardiovascular drugs including antihypertensive pharmacological agents seem to be inefficient to provide appropriate therapeutic effects during cold exposure. Therefore, it is imperative to propose alternative non-pharmacological therapies intended to prevent the detrimental effects of low environmental temperatures on cardiovascular function. Recently, oral supplementation of the amino acid L-citrulline has been proposed as an effective therapeutic adjuvant for the treatment of hypertension. L-citrulline is known to enhance the bioavailability of L-arginine levels and increase endothelial nitric oxide (NO) production, one of the main modulators of vascular tone and blood pressure (BP). L-citrulline supplementation has been shown to increase endothelial function, reduce BP, and ameliorate endothelial oxidative damage without any adverse effects. Our group has demonstrated that L-citrulline supplementation attenuates the BP response to cold exposure (the cold pressor test, CPT). These studies suggest that L-citrulline supplementation may be a feasible therapeutic aid in order to prevent cardiovascular complications associated with cold exposure. However the potential cardioprotective effects of L-citrulline supplementation during cold exposure with exercise have yet to be evaluated. It is hypothesized that L-citrulline supplementation would reduce arterial stiffness and blood pressure (BP) responses to physiological stress (cold exposure). This study may lead to the development of an adjunct therapy for the prevention and management of cardiovascular adverse events that are particularly increased during the winter months.
Detailed Description
The specific aims of the study are:
AIM 1: To determine the acute effects of cold exposure and isometric exercise, on cardiovascular hemodynamics and autonomic regulation. The working hypothesis is that the combination of cold exposure with isometric hand grip (IHG) exercise would evoke a greater acute increase in arterial stiffness, wave reflection, arterial BP and sympathetic activity than cold exposure or IHG alone. In order to test this hypothesis, the investigators will use an environmental chamber at a temperature of 4oC to perform non-invasive measurements of arterial stiffness (carotid-femoral, femoral-ankle, and brachial-ankle pulse wave velocity [PWV]), pulse wave analysis (aortic BP and augmentation index [AIx]) using applanation tonometry of the radial artery. In addition, the investigators will use continuous beat-by-beat digital BP, power spectral analysis of heart rate variability and blood pressure variability, and spontaneous BRS to evaluate autonomic function during cold exposure.
AIM 2: To examine the effects of L-citrulline supplementation on cardiovascular hemodynamics, autonomic regulation and endothelial function. The investigators will test the working hypothesis that L-citrulline supplementation for 14 days will attenuate the cardiovascular responses to physiological stress. The investigators will perform the same procedures previously specified in AIM I.
AIM 3: To determine the acute and chronic L-citrulline supplementation on endothelial function by measuring flow-mediated vasodilation, vasoactive substances, and Endothelial Progenitor Cells (EPCs). This aim will examine the working hypothesis L-citrulline will result in greater circulating levels of vasodilatory substances including nitric oxide, prostacyclin, and EPCs whereas vasoconstrictor substances endothelin-I (ET-1) will decrease. This aim will be tested by measuring serum levels of these substances before and immediately after the session at baseline and 7 days after the intervention.
Description of the study Forty individuals (20 men and 20 women) 18-35 years of age with normal resting BP (< 140/90 mmHg) will be enrolled in this study. Subjects should not be smokers, L-citrulline users or regular exercisers (defined as more than 120 min per week) in the last 6 months. The exclusion criteria will be any contraindication to exercise and medical conditions. Subjects with diverse ethnic backgrounds will be recruited from the Tallahassee metropolitan area by advertisement and direct communication.
Study design:
After completion of initial screening, cardiovascular function of eligible subjects will be evaluated at a room temperature of 4oor 23oC in random order. After baseline measurements, subjects will be randomly assigned to Placebo (Malt dextrin) or L-citrulline group for 14 days. Cardiovascular function will be evaluated at the end of the study.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
wave reflection, augmentation Index, heart rate variability, wasted left ventricular energy
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 1, Phase 2
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
16 (Actual)
8. Arms, Groups, and Interventions
Arm Title
L-citrulline
Arm Type
Experimental
Arm Description
L-citrulline (100mg/kg of body weight per day for 2 weeks)
Arm Title
Maltodextrin
Arm Type
Placebo Comparator
Arm Description
6g/day of placebo (maltodextrin)
Intervention Type
Dietary Supplement
Intervention Name(s)
L-citrulline
Intervention Description
2 weeks of L-citrulline supplementation (100mg/kg of body weight).
Primary Outcome Measure Information:
Title
Blood Pressure
Description
By measuring brachial and central (aortic and carotid) BP at rest and during physiological stress (cold exposure and handgrip test)
Time Frame
6 weeks
Secondary Outcome Measure Information:
Title
Autonomic control of heart rate
Description
By measuring heart rate variability at rest and during physiological stress.
Time Frame
6 weeks
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
35 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Men
Blood pressure lower than 140/90mmHg
Age 18 to 35 years
BMI 20-39 kg/m2
Exclusion Criteria:
Blood Pressure >160/100 mmHg
Asthma
Glaucoma
Herpes simplex
Uncontrolled diabetes
Neurological disease
Cardiovascular disease
Inflammatory disease
Kidney disease
Hormone replacement therapy (HRT)
Amino acid/vitamin supplementation\
Corticosteroids or non-steroidal anti-inflammatory drugs
Any drug known to affect BP or heart rate
Glycemic control drugs
Lipids reducing drugs
Participants should not consume > 12 alcoholic drink/week
Smokers
Regular Exercisers (>1.5 hour/week).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Marcos A Sanchez-Gonzalez, M.D.
Organizational Affiliation
The Florida State University
Official's Role
Principal Investigator
Facility Information:
Facility Name
FSU College of Human Sciences
City
Tallahassee
State/Province
Florida
ZIP/Postal Code
32306
Country
United States
12. IPD Sharing Statement
Learn more about this trial
L-citrulline Supplementation & Cold Exposure
We'll reach out to this number within 24 hrs